| The stimulation of thrombosis by hypoxia |
86 |
| Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis |
57 |
| Lupus anticoagulant identifies two distinct groups of patients with different antibody patterns |
20 |
| Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer |
19 |
| An update on factor XI structure and function |
19 |
| Epidemiology of the post-thrombotic syndrome |
19 |
| Simple method for removing DOACs from plasma samples |
18 |
| Neutralising rivaroxaban induced interference in laboratory testing for lupus anticoagulant (LA): A comparative study using DOAC Stop and andexanet alfa |
17 |
| The role of neutrophils in thrombosis |
17 |
| Exosomes of bone-marrow stromal cells inhibit cardiomyocyte apoptosis under ischemic and hypoxic conditions via miR-486-5p targeting the PTEN/PI3K/AKT signaling pathway |
16 |
| Late outcomes of pulmonary embolism: The post-PE syndrome |
16 |
| Arterial thrombosis and cancer |
14 |
| Risk factors for inhibitor development in severe hemophilia a |
13 |
| MiR-188-3p upregulation results in the inhibition of macrophage proinflammatory activities and atherosclerosis in ApoE-deficient mice |
13 |
| Direct oral anticoagulants in patients with liver cirrhosis: A systematic review |
13 |
| Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: A systematic review and meta-analysis |
13 |
| The safest and most efficacious route of tranexamic acid administration in total joint arthroplasty: A systematic review and network meta-analysis |
13 |
| Risk of venous and arterial thrombosis in non-surgical patients receiving systemic tranexamic acid: A systematic review and meta-analysis |
13 |
| Resumption of anticoagulant therapy after anticoagulant-related gastrointestinal bleeding: A systematic review and meta-analysis |
12 |
| Interplay between genetics and epigenetics in modulating the risk of venous thromboembolism: A new challenge for personalized therapy |
11 |
| Effect of low and moderate dose FEIBA to reverse major bleeding in patients on direct oral anticoagulants |
11 |
| Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: Comparative effectiveness, safety, and costs |
11 |
| A multi-institutional registry of pediatric hospital-acquired thrombosis cases: The Children's Hospital-Acquired Thrombosis (CHAT) project |
11 |
| The effect of bariatric surgery on direct-acting oral anticoagulant drug levels |
11 |
| A review of global coagulation assays - Is there a role in thrombosis risk prediction? |
11 |
| Contribution of platelets, the coagulation and fibrinolytic systems to cutaneous wound healing |
10 |
| The genetics of antithrombin |
10 |
| Mechanisms coupling thrombin to metastasis and tumorigenesis |
10 |
| Measuring functional limitations after venous thromboembolism: A call to action |
10 |
| The impact of post-pulmonary embolism syndrome and its possible determinants |
10 |
| Morbidity and mortality after fragility hip fracture surgery in patients receiving vitamin K antagonists and direct oral anticoagulants |
10 |
| Incidence, risk factors, and outcomes of venous thromboembolism after oncologic surgery: A systematic review and meta-analysis |
10 |
| Neutrophils and neutrophil-lymphocyte ratio: Inflammatory markers associated with intimal-media thickness of atherosclerosis |
10 |
| Anticoagulation during ECMO in neonatal and paediatric patients |
10 |
| Platelets, NETs and cancer |
9 |
| Significance of plasma fibrinogen level and antithrombin activity in sepsis: A multicenter cohort study using a cubic spline model |
9 |
| Effects of platelets on cancer progression |
9 |
| Hemostatic biomarkers in cancer progression |
9 |
| IgG phosphatidylserine/prothrombin antibodies as a risk factor of thrombosis in antiphospholipid antibody carriers |
9 |
| Red cell distribution width as a predictor of 1-year survival in ischemic stroke patients treated with intravenous thrombolysis |
9 |
| Networks that stop the flow: A fresh look at fibrin and neutrophil extracellular traps |
9 |
| Protection of the endothelial glycocalyx by antithrombin in an endotoxin-induced rat model of sepsis |
9 |
| Cancer-associated ischemic stroke: A retrospective multicentre cohort study |
9 |
| Testosterone therapy and venous thromboembolism: A systematic review and meta-analysis |
9 |
| Rivaroxaban versus warfarin for the prevention of post-thrombotic syndrome |
9 |
| Predicting the risk of recurrent venous thromboembolism in patients with cancer: A prospective cohort study |
9 |
| A prospective study of Rivaroxaban for central venous catheter associated upper extremity deep vein thrombosis in cancer patients (Catheter 2) |
9 |
| Residual pulmonary embolism as a predictor for recurrence after a first unprovoked episode: Results from the REVERSE cohort study |
8 |
| Low-molecular-weight heparin treatment for portal vein thrombosis in liver cirrhosis: Efficacy and the risk of hemorrhagic complications |
8 |
| HERDOO2 clinical decision rule to guide duration of anticoagulation in women with unprovoked venous thromboembolism. Can I use any D-Dimer? |
8 |
